Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | UBE2N | P61088 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5428767 | 0.92 | MAPT (0.53) | TSHRALDH1A1HPGDGAAMAPT | |
| SCHEMBL5425614 | 0.86 | MAPT (0.57) | ALDH1A1HPGDLMNAMAPTSMN1; SMN2 | |
| SCHEMBL5814760 | 0.81 | KLK6 (0.55) | TSHRALDH1A1HPGDLMNAMAPT | |
| SCHEMBL15143031 | 0.74 | KMT2A (0.68) | ALDH1A1HPGDGAAMAPTPOLB | |
| SCHEMBL29506259 | 0.74 | CNR1 (0.78) | TSHRALDH1A1HPGDATMTP53 | |
| SCHEMBL31447965 | 0.74 | MAPT (0.70) | ALDH1A1HPGDGAALMNAMAPT | |
| SCHEMBL28374383 | 0.74 | MAPT (0.56) | ALDH1A1HPGDGAAMAPTPOLB | |
| SCHEMBL28880300 | 0.74 | TSHR (0.81) | TSHRALDH1A1TP53GAALMNA | |
| SCHEMBL16026455 | 0.72 | MAPT (0.82) | TSHRALDH1A1GAALMNAMAPT | |
| SCHEMBL31488466 | 0.72 | TSHR (0.76) | TSHRALDH1A1HPGDATMTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185115-A1 | Novel ureido-and amido-pyrazolone derivatives | ASTON UNIVERSITY (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185115-A1 | Novel ureido-and amido-pyrazolone derivatives | ASTON UNIVERSITY (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185115-A1 | Novel ureido-and amido-pyrazolone derivatives | ASTON UNIVERSITY (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1628963-A1 | NOVEL UREIDO - AND AMIDO-PYRAZOLONE DERIVATIVES | Aston University (GB) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004106306-A1 | NOVEL UREIDO - AND AMIDO-PYRAZOLONE DERIVATIVES | ASTON UNIVERSITY (GB) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185115-A1 | Novel ureido-and amido-pyrazolone derivatives | CCKAR, CCKBR, GRPR | TSHR 116/4885ALDH1A1 2093/4885HPGD 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.